Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 13, 2026 in Aardvark Therapeutics, Inc. Lawsuit - AARD

A securities class action alleges Aardvark Therapeutics' SEC filings warned about clinical risk in generic terms while describing ARD-101 as "99% restricted to the gut" with "no serious adverse events" and "no renal or hepatic safety limitations" — language the complaint contends did not disclose the specific cardiac safety issues that later drew a full FDA clinical hold.